Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial

Pimentel, Mark, Park, Sandy, Mirocha, James, Kane, Sunanda V., Kong, Yuthana · 2006 · Annals of Internal Medicine

Abstract

BACKGROUND: Alterations in gut flora may be important in the pathophysiology of the irritable bowel syndrome (IBS). OBJECTIVE: To determine whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS. DESIGN: Double-blind, randomized, placebo-controlled study. SETTING: 2 tertiary care medical centers. PARTICIPANTS: 87 patients who met Rome I criteria for IBS and were enrolled from December 2003 to March 2005. INTERVENTIONS: Participants who met enrollment criteria were randomly assigned to receive 400 mg of rifaximin 3 times daily for 10 days (n = 43) or placebo (n = 44). Eighty participants completed rifaximin therapy or placebo, and follow-up data were available for at least 34 participants per study group at any time point thereafter. MEASUREMENTS: A questionnaire was administered before treatment and 7 days after treatment. The primary outcome was global improvement in IBS. Patients were then asked to keep a weekly symptom diary for 10 weeks. RESULTS: Over the 10 weeks of follow-up, rifaximin resulted in greater improvement in IBS symptoms (P = 0.020). In addition, rifaximin recipients had a lower bloating score after treatment. LIMITATIONS: The major limitations of the study were its modest sample size and short duration and that most patients were from 1 center. CONCLUSIONS: Rifaximin improves IBS symptoms for up to 10 weeks after the discontinuation of therapy.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-145-8-200610170-00004

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 6

  1. Wilson S, 2004, Br J Gen Pract, 54, 495
  2. El-Serag HB, 2003, Rev Gastroenterol Disord, 3, S3
  3. Pimentel M, 2003, Am J Gastroenterol, 98, 412
  4. Veldhuyzen van Zanten SJ, 1999, Gut, 45, II69
  5. Balsari A, 1982, Microbiologica, 5, 185
  6. Cuoco L, 2006, Minerva Gastroenterol Dietol, 52, 89

Cited by

See all 466

Metadata

Authors
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y.
Affiliations
Cedars-Sinai Medical Center (US)
Venue
Annals of Internal Medicine
Published
2006-10-17
Volume
145
Issue
8
Pages
557-563
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2103771013
Cited by
466
References
28
Citations by year
2026: 8 · 2025: 6 · 2024: 3 · 2023: 10 · 2022: 8 · 2021: 14 · 2020: 12 · 2019: 13 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 26 · 2014: 26 · 2013: 21 · 2012: 33
FWCI
34.49
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Annals of Internal Medicine
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
irritable bowel syndrome, rifaximin, gut microbiota, IBS symptoms, bloating, symptom improvement, placebo comparison
MeSH terms
Rifaximin, Adolescent, Adult, Aged, Anti-Infective Agents, Blind Loop Syndrome, Double-Blind Method, Female, Follow-Up Studies, Gastrointestinal Agents, Humans, Male, Middle Aged, Rifamycins, Treatment Outcome, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-145-8-200610170-00004
The paper
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006). The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-8-200610170-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.